Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 14 | 2024 | 1877 | 2.940 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 4 | 2024 | 65 | 1.980 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2024 | 1237 | 1.850 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2024 | 716 | 1.560 |
Why?
|
| Anticholesteremic Agents | 2 | 2024 | 231 | 1.420 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 34 | 0.920 |
Why?
|
| Incretins | 1 | 2024 | 25 | 0.910 |
Why?
|
| Ageism | 1 | 2023 | 4 | 0.860 |
Why?
|
| Glucose Intolerance | 1 | 2024 | 75 | 0.850 |
Why?
|
| Hypoglycemic Agents | 4 | 2024 | 429 | 0.830 |
Why?
|
| Vascular Stiffness | 1 | 2023 | 75 | 0.810 |
Why?
|
| Obesity | 5 | 2024 | 2233 | 0.730 |
Why?
|
| Hypercholesterolemia | 1 | 2022 | 226 | 0.680 |
Why?
|
| Insulin Resistance | 2 | 2024 | 641 | 0.650 |
Why?
|
| Atherosclerosis | 2 | 2024 | 834 | 0.650 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 850 | 0.590 |
Why?
|
| Hypertension | 1 | 2023 | 1286 | 0.470 |
Why?
|
| Lipids | 2 | 2023 | 514 | 0.340 |
Why?
|
| Cholesterol, LDL | 2 | 2024 | 559 | 0.330 |
Why?
|
| Risk Factors | 6 | 2024 | 10042 | 0.290 |
Why?
|
| Humans | 21 | 2024 | 123311 | 0.280 |
Why?
|
| Nutrition Surveys | 2 | 2024 | 290 | 0.250 |
Why?
|
| Mitochondria, Muscle | 1 | 2024 | 34 | 0.230 |
Why?
|
| Anti-Obesity Agents | 1 | 2024 | 42 | 0.230 |
Why?
|
| Proprotein Convertase 9 | 1 | 2024 | 67 | 0.220 |
Why?
|
| Standard of Care | 1 | 2024 | 129 | 0.220 |
Why?
|
| Pulse Wave Analysis | 1 | 2023 | 47 | 0.220 |
Why?
|
| Exercise Tolerance | 1 | 2024 | 77 | 0.210 |
Why?
|
| Glucose Tolerance Test | 1 | 2024 | 209 | 0.210 |
Why?
|
| Weight Loss | 2 | 2024 | 480 | 0.210 |
Why?
|
| Cardiovascular System | 1 | 2024 | 101 | 0.210 |
Why?
|
| Cause of Death | 1 | 2024 | 463 | 0.200 |
Why?
|
| Blood Glucose | 2 | 2024 | 1122 | 0.200 |
Why?
|
| Fatty Liver | 1 | 2024 | 178 | 0.200 |
Why?
|
| Patient Care | 1 | 2023 | 100 | 0.200 |
Why?
|
| Obesity Management | 1 | 2021 | 2 | 0.190 |
Why?
|
| Sulfonylurea Compounds | 1 | 2021 | 16 | 0.190 |
Why?
|
| Prediabetic State | 1 | 2022 | 57 | 0.190 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2021 | 25 | 0.190 |
Why?
|
| Hypolipidemic Agents | 1 | 2023 | 176 | 0.190 |
Why?
|
| Thiazolidinediones | 1 | 2021 | 79 | 0.180 |
Why?
|
| Overweight | 1 | 2023 | 358 | 0.180 |
Why?
|
| Leg | 1 | 2021 | 155 | 0.170 |
Why?
|
| Ergocalciferols | 1 | 2019 | 4 | 0.170 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 116 | 0.170 |
Why?
|
| Insulin | 2 | 2021 | 1205 | 0.160 |
Why?
|
| Albuminuria | 1 | 2019 | 92 | 0.160 |
Why?
|
| Vitamins | 1 | 2019 | 107 | 0.160 |
Why?
|
| Life Style | 1 | 2021 | 404 | 0.160 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 520 | 0.160 |
Why?
|
| Aged | 7 | 2024 | 19174 | 0.150 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 71 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 1142 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1084 | 0.140 |
Why?
|
| Comorbidity | 1 | 2021 | 1498 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2024 | 796 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1259 | 0.120 |
Why?
|
| United States | 6 | 2024 | 10667 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 716 | 0.110 |
Why?
|
| Exercise | 3 | 2024 | 816 | 0.100 |
Why?
|
| Adult | 8 | 2024 | 29087 | 0.100 |
Why?
|
| Male | 7 | 2024 | 60285 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2021 | 6032 | 0.090 |
Why?
|
| Veterans | 1 | 2022 | 1735 | 0.090 |
Why?
|
| Female | 7 | 2024 | 65618 | 0.090 |
Why?
|
| Middle Aged | 5 | 2024 | 26075 | 0.070 |
Why?
|
| Prevalence | 2 | 2024 | 2407 | 0.070 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 939 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3382 | 0.060 |
Why?
|
| Glycolysis | 1 | 2024 | 143 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2024 | 288 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 228 | 0.050 |
Why?
|
| Mitochondrial Diseases | 1 | 2024 | 135 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 68 | 0.050 |
Why?
|
| Public Health | 1 | 2024 | 260 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 253 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2024 | 221 | 0.050 |
Why?
|
| Longevity | 1 | 2022 | 138 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2022 | 313 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 8871 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2021 | 307 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 2001 | 0.040 |
Why?
|
| Heart | 1 | 2024 | 723 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1172 | 0.040 |
Why?
|
| Placebos | 1 | 2019 | 240 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2019 | 255 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2019 | 147 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2024 | 3240 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3568 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2021 | 795 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 19132 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1686 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1600 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3337 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1390 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 6387 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2024 | 16066 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12168 | 0.010 |
Why?
|